Prodrugs of phosphates, phosphonates, and phosphinates

Advanced Drug Delivery Reviews

Volumn 19, Issue 2, 1996, Pages 287-310

  Krise, Jeffrey P ^a   Stella, Valentino J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Bioavailability; Ester; Nucleotide analog; Nucleotide prodrug; Permeability

Indexed keywords

AGENTS; CARBOHYDRATES; DERIVATIVES; DRUG THERAPY; ENZYME INHIBITION; ENZYMES; ESTERS; MECHANICAL PERMEABILITY; PHOSPHATES;

BIOAVAILABILITY; DRUG DELIVERY; NUCLEOTIDE ANALOG; NUCLEOTIDE PRODRUG; PHOSPHINATES; PHOSPHONATES; PRODRUGS;

DRUG PRODUCTS;

(HYDROXY 2 NAPHTHALENYLMETHYL)PHOSPHONIC ACID; ACETYLTHIOETHANOL; ADEFOVIR; CGS 24562; DITHIODIETHANOL; FLOXURIDINE PHOSPHATE; FOSINOPRIL; L 690330; PHOSPHATE; PHOSPHOLIPID; PHOSPHONIC ACID DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG STABILITY; MEMBRANE PERMEABILITY; PRIORITY JOURNAL; REVIEW;

EID: 0343844454     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-409X(95)00111-J     Document Type: Review

References (140)

1. Perigaud, C., Gosselin, G. and Imbach, J. (1992) Nucleoside analogues as chemotherapeutic agents: A review. Nucleosides Nucleotides 11, 903-945.
2. Bryson, V.J. and Connor, J.D. (1976) In vitro susceptibility of varicella zoster virus to adenine arabinoside and hypoxanthine arabinoside. Antimicrob. Agents Chemother. 9, 540-543.
3. Cooney, D.A., Dalal, M., Mitsuya, H., McMahon, J.B., Nadkarni, M., Balzarini, J., Brodor, S. and Johns, D.G. (1986) Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem. Pharm. 35, 2065-2068.
4. Cohen, S.S., Flaks, J.G., Barner, H.D., Loeb, M.R., Lichtenstein, J. (1958) The mode of action of 5-fluorouracil and its derivatives. Proc. Natl. Acad. Sci. USA 44, 1004-1012.
5. Armstrong, D., Gold, J.W.M., Dryjanski, J., Whimbey, E., Polsky, B., Hawkins, C., Brown, A.E., Bernard, E. and Kiehn, T.E. (1985) Treatment of infections in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 103, 738-743.
6. LePage, G.A. (1963) Basic biochemical effects and mechanism of action of 6-thioguanine, Cancer Res. 23, 1202-1206.
7. Neil, G.L., Wiley, P.F., Manak, R.C. and Moxley, T.E. (1970) Antitumor effect of 1-beta-D-arabinofuranosylcytosine 5′-adamantoate (NSC 117614) in L1210 leukemic mice. Cancer Res. 30, 1047-1054.
8. York, J.L. and LePage, G.A. (1966) A proposed mechanism for the action of 9-beta-D-arabinofuranosyladenine as an inhibitor of the growth of some ascites cells. Can. J. Biochem. 44, 19-26.
9. Uchida, K. and Kreis, W. (1969) Studies on drug resistance - I. Distribution of 1-beta-D-arabinofuranosylcytosine, cytidine and deoxycytidine in mice bearing ara-C-sensitive and resistant P815 neoplasms. Biochem. Pharmacol. 18, 1115-1128.
10. Reichard, P., Skold, O.K., G., Revesz, L. and Magnusson, P. (1962) Studies on resistance against 5-fluorouracil I. Enzymes of the uracil pathway during development of resistance. Cancer Res. 22, 235-243.
11. Bapat, A.B., Zarow, C. and Danenberg, P.V. (1983) Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J. Biol. Chem. 258, 4130-4136.
12. Johnson, M.A. and Fridland, A. (1989) Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36, 291-295.
13. Balzarini, J., Cooney, D.A., Dalal, M., Kang, G., Cupp, J.E., De Clercq, E., Brodor, S. and Johns, D.G. (1987) 2′,3′-dideoxycytidine: Regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32, 798-806.
14. Starnes, M.C. and Cheng, Y. (1987) Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262, 988-991.
15. Johnson, M.A., Ahluwalia, G., Connelly, M.C., Conney, D.A., Brodor, S., Johns, D.G. and Fridland, A. (1988) Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 263, 15354-15357.
16. Posternak, T. (1974) Cyclic AMP and cyclic GMP. Annu. Rev. Pharmacol. 14, 23-33.
17. Lichtenstein, J., Barner, H.D. and Cohen, S.S. (1960) The metabolism of exogenously supplied nucleotides by Escherichia coli. J. Biol. Chem. 235, 457-465.
18. Leibman, K.C. and Heidelberger, C. (1955) The Metabolism of P32-labeled ribonucleotides in tissue slices and cell suspensions. J. Biol. Chem. 216, 823-830.
19. Roll, P.M., Weinfeld, H., Carroll, E. and Brown, G.B. (1956) The utilization of nucleotides by the mammal. IV. Triply labeled purine nucleotides. J. Biol. Chem. 220, 439-454.
20. Schrecker, A.W. and Goldin, A. (1968) Antitumor effect and mode of action of 1-beta-D-arabinofuranosylcytosine 5′-phosphate in leukemia L1210. Cancer Res. 28, 802-803.
21. Lepage, G.A., Naik, S.R., Katakkar, S.B. and Khaliq, A. (1975) 9-β-D-Arabinofuranosyladenine 5′-phosphate metabolism and excretion in humans. Cancer Res. 35, 3036-3040.
22. Ho, D.H.W. (1971) Metabolism of 6-methylthiopurine ribonucleoside 5′-phosphate. Biochem. Pharmacol. 20, 3538-3539.
23. Holy, A. (1993) Isopolar phosphorus-modified nucleotide analogues. In: E. De Clercq (Ed.), Advances in Antiviral Drug Design, Jai Press Inc., Leuven, pp. 179-231.
24. Bundgaard, H. (1985) Design of Prodrugs: Bioreversible derivatives for various functional groups and chemical entities. In: H. Bundgaard (Ed.), Design of Prodrugs, Elsevier, pp. 1-97.
25. Jones, R.J., Bischofberger, N. (1995) Minireview: nucleotide prodrugs. Antiviral Res. 27, 1-17.
26. Rosowsky, A., Kim, S., Ross, J. and Wick, M.M. (1982) Lipophilic 5′-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl derivatives as potential prodrugs. J. Med. Chem. 25, 171-178.
27. Mullah, K.B., Roa, T.S., Balzarini, J., De Clercq, E. and Bentrude, W.G. (1992) Potential prodrug derivatives of 2′,3′-didehydro-2′,3′-dideoxynucleosides. Preparations and antiviral activities. J. Med. Chem. 35, 2728-2735.
28. Montgomery, J.A., Schabel, P.M., Jr. and Skipper, H.E. (1962) Experimental evaluation of potential anticancer agents. IX. The ribonucleosides and ribonucleotides of two purine antagonists. Cancer Res. 22, 504-509.
29. McGuigan, C., Bellevergue, P., Jones, B.C.N.M., Mahmood, N., Hay, A.J., Petrik, J. and Karpas, A. (1994) Alkyl hydrogen phosphonate derivatives of the anti-HIV agent AZT may be less toxic than the parent nucleoside analogue. Antiviral Chem. Chemother. 5, 271-277.
30. Colin, B., Jones, N.M., McGuigan, C. and Riley, P.A. (1989) Synthesis and biological evaluation of some phosphate triester derivatives of the anti-cancer drug araC. Nucleic Acids Res. 17, 7195-7201.
31. McGuigan, C., Shackleton, J.M., Tollerfield, S.M. and Riley, P.A. (1989) Synthesis and evaluation of some novel phosphate and phosphinate derivatives of araA. Studies on the mechanism of action of phosphate triesters. Nucleic Acids Res. 17, 10171-10177.
32. McGuigan, C., Tollerfield, S.M. and Riley, P. (1989) Synthesis and biological evaluation of some phosphate triester derivatives of the anti-viral drug araA. Nucleic Acids Res. 17, 6065-6075.
33. McGuigan, C., Nicholls, S.R., O'Connor, T.J. and Kinchington, D. (1990) Synthesis of some novel dialkyl phosphate derivatives of 3′-modified nucleosides as potential anti-AIDS drugs. Antiviral Chem. Chemother. 1, 25-33.
34. Devine, K.G., McGuigan, C., O'Connor, T.J., Nicholls, S.R. and Kinchington, D. (1990) Novel phosphate derivatives of zidovudine as anti-HIV compounds. AIDS 4, 371-372.
35. Serafinowska, H.T., Ashton, R.J., Baily, S., Harnden, M.R. and Sutton, D. (1995) Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy] adenine. J. Med. Chem. 38, 1372-1379.
36. Russell, J.W., Marrero, D., Whiterock, V.J., Klunk, J. and Starrett, J.E. (1991) Determination of 9-[(2-phosphonylmethoxy)ethyl]adenine in rat urine by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 572, 321-326.
37. Balzarini, J., Naesens, L., Slachmuylders, J., Niphuis, H., Rosenberg, I., Holy, A., Schellenkens, H. and De Clercq, E. (1991) 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 5, 21-28.
38. Starrett, J.E., Jr., Tortolani, D.R., Russell, J., Hitchcock, M.J.M., Whiterock, V., Martin, J.C. and Mansuri, M.M. (1994) Synthesis, oral bioavailability determination, and in vitro evaluation of prodrugs of the antiviral agent 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). J. Med. Chem. 37, 1857-1864.
39. Montgomery, J.A., Thomas, H.J. and Schaeffer, H.J. (1961) Synthesis of potential anticancer agents. XXVIII. Simple esters of 6-mercaptopurine ribonucleotide. J. Org. Chem. 26, 1929-1933.
40. Thomas, H.J. and Montgomery, J.A. (1968) Derivatives and analogs of 6-mercaptopurine ribonucleotide. J. Med. Chem. 11, 44-48.
41. McGuigan, C., Pathirana, R.N., Davis, M.P.H., Balzarini, J. and De Clercq, E. (1994) Diaryl phosphate derivatives act as pro-drugs of AZT with reduced cytotoxicity compared to the parent nucleoside. Bioorg. Med. Chem. Lett. 4, 427-430.
42. Chawla, R.R., Freed, J.J. and Hampton, A. (1984) Bis(m-nitrophenyl) and bis(p-nitrophenyl) esters ant the phosphoramidate of thymidine 5′-phosphate as potential sources of intracellular thymidine 5′-phosphate in mouse cells in culture. J. Med. Chem. 27, 1733-1736.
43. McGuigan, C., Pathirana, R.N., Mahmood, N., Devine, K.G. and Hay, A.J. (1992) Aryl phosphate derivatives of AZT retain activity against HIV 1 in cell lines which are resistant to the action of AZT. Antiviral Res. 17, 311-321.
44. De Lombaert, S., Singh, K.B., L. and Soliman, V.F. (1994) Chemical and plasma hydrolyses of a diphenyl alpha-aminomethyl phosphonate prodrug inhibitor of neutral endopeptidase 24.11. Bioorg. Med. Chem. Lett. 4, 899-902.
45. De Lombaert, S., Erion, M.D., Tan, J.B., El-Chehabi, L., Ghai, R.D., Sakane, Y., Berry, C. and Trapani, A.J. (1994) N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. J. Med. Chem. 37, 498-511.
46. Mitchell, A.G., Nicholls, D., Walker, I., Irwin, W.J. and Freeman, S. (1991) Prodrugs of phosphonoformate: Products, kinetics and mechanism of hydrolysis of dibenzyl (methoxycarbonyl) phosphonate. J. Chem. Soc. Perkin Trans. 2 1297-1303.
47. Mitchell, A.G., Nicholls, D., Irwin, W.J. and Freeman, S. (1992) Prodrugs of phosphonoformate: The effect of para-substituents on the products, kinetics and mechanism of hydrolysis of dibenzyl methoxycarbonylphosphonate. J. Chem. Soc. Perkin Trans. 2 1145-1150.
48. Repta, A.J., Rawson, B.J., Shaffer, R.D., Sloan, K.B., Bodor, N. and Higuchi, T. (1975) Rational development of a soluble prodrug of a cytotoxic nucleoside: Preparation and properties of arabinosyladenine 5′-formate. J. Pharm. Sci. 64, 392-396.
49. Engel, R. (1977) Phosphonates as analogues of natural phosphates. Chem. Rev. 77, 349-367.
50. Nacsens, L., Balzarini, J., Alexander, P., Holy, A. and De Clercq, E. (1994) Antiretroviral efficacy and pharmacokinetics of ester prodrugs of 9-(2-phosphonylmethoxy-ethyl) adenine (PMEA). Antiviral Res. 23 (Suppl. 1), 64.
51. McGuigan, C., Kinchington, D., Wang, M.F., Nicholls, S.R., Nickson, C., Galpin, S., Jeffries, D.J. and O'Connor, T.J. (1993) Nucleoside analogues previously found to be inactive against HIV may be activated by simple phosphorylation. FEBS Lett. 322, 249-252.
52. McGuigan, C., O'Connor, T.J., Nicholls, S.R., Nickson, C. and Kinchington, D. (1990) Synthesis and anti-HIV activity of some novel substituted dialkyl phosphate derivatives of AZT and ddCyd. Antiviral Chem. Chemother. 1, 355-360.
53. McGuigan, C., Jones, B.C.N.M., Tollerfield, S.M. and Riley, P.A. (1992) Synthesis and biological evaluation of haloalkyl phosphate triester derivatives of araA and araC. Antiviral Chem. Chemother. 3, 79-84.
54. McGuigan, C., Turner, S., Nicholls, S.R., O'Connor, T.J. and Kinchington, D. (1994) Haloalkyl phosphate derivatives of AZT as inhibitors of HIV: studies in the phosphate region. Antiviral Chem. Chemother. 5, 162-168.
55. Kelly, S.J. and Butler, L.G. (1975) Enzymic hydrolysis of phosphonate esters. Biochem. Biophys. Res. Commun. 66, 316-321.
56. Kelly, S.J., Dardinger, D.E. and Butler, L.G. (1975) Hydrolysis of phosphonate esters catalyzed by 5′-nucleotide phosphodiesterase. Biochemistry 14, 4983-4988.
57. Kelly, S.J. and Butler, L.G. (1977) Enzymic hydrolysis of phosphonate esters. Reaction mechanism of intestinal 5′-nucleotide phosphodiesterase. Biochemistry 16, 1102-1104.
58. Landt, M., Everard, R.A. and Butler, L.G. (1980) 5′-Nucleotide phosphodiesterase: Features of the substrate binding site as deduced from specificity and kinetics of some novel substrates. Biochemistry 19, 138-143.
59. McGuigan, C., Nickson, C., Petrik, J. and Karpas, A. (1992) Phosphate derivatives of AZT display enhanced selectivity of action against HIV1 by comparison to the parent nucleoside. FEBS Lett. 310, 171-174.
60. Iyer, R.P., Phillips, L.R., Biddle, J.A., Thakker, D.R. and Egan, W. (1989) Synthesis of acyloxyalykyl acylphosphonates as potential prodrugs of the antiviral, trisodium phosphonoformate (foscarnet sodium). Tetrahedron Lett. 30, 7141-7144.
61. Farquhar, D. (1985) Neutral 5-fluoro-2′-deoxynucleoside 5′-monophosphate (FdUMP) esters as potential membrane-transport precursors of FdUMP. Proc. Am. Assoc. Cancer Res. 26, 248.
62. Starrett, J.E.J., Tortolani, D.R., Hitchcock, M.J.M., Martin, J.C. and Mansuri, M.M. (1992) Synthesis and in vitro evaluation of a phosphonate prodrug: bis-(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl) adenine. Antiviral Res. 19, 267-273.
63. Sastry, J.K., Nehete, P.N., Khan, S., Nowak, B.J., Plunkett, W., Arlinghaus, R.B. and Farquhar, D. (1992) Membrane-permeable dideoxyuridine 5′-monophosphate analog inhibits human immunodeficiency virus infection. Mol. Pharmacol. 41, 441-445.
64. Freed, J.J., Farquhar, D. and Hampton, A. (1989) Evidence for acyloxymethyl esters of pyrimidine 5′-deoxyribonucleotides as extracellular sources of active 5′-deoxyribonucleotides in cultured cells. Biochem. Pharmacol. 38, 3193-3198.
65. Srinivas, R.V., Robbins, B.L., Connelly, M.C., Gong, Y., Bischofberger, N. and Fridland, A. (1993) Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 37, 2247-2250.
66. Shaw, J.P. and Cundy, K.C. (1993) Biological screens of PMEA prodrugs. Pharm. Res. 10 (Suppl.), S294.
67. Cundy, K.C., Fishback, J.A., Shaw, J.P., Lee, M.L., Soike, K.F., Visor, G.C. and Lee, W.A. (1994) Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11, 839-843.
68. Pompon, A., Lefebvre, I., Imbach, J., Kahn, S. and Farquhar, D. (1994) Decomposition pathways of the mono- and bis(pivaloyloxymethyl) esters of azidothymidine 5′-monophosphate in cell extract and in tissue culture medium: an application of the 'on-line ISRP-cleaning' HPLC technique. Antiviral Chem. Chemother. 5, 91-98.
69. Farquhar, D., Srivastva, D.N., Kuttesch, N.J. and Saunders, P.P. (1983) Biologically reversible phosphate-protective groups. J. Pharm. Sci. 72, 324-325.
70. Srivastva, D.N. and Farquhar, D. (1984) Bioreversible phosphate protective groups: Synthesis and stability of model acyloxymethyl phosphates. Bioorg. Chem. 12, 118-129.
71. Mitchell, A.G., Thompson, W., Nicholls, D., Irwin, W.J. and Freeman, S. (1992) Bioreversible protection for the phospho group: Bioactivation of the di(4-acyloxybenzyl) and mono(4-acyloxybenzyl) phosphoesters of methylphosphonate and phosphonoacetate. J. Chem. Soc. Perkin Trans. 1 2345-2353.
72. Thompson, W., Nicholls, D., Irwin, W.J., Al-Mushadani, J.S., Freeman. S., Karpas, A., Petrik, J., Mahmood, N. and Hay, A.J. (1993) Synthesis, bioactivation and anti-HIV activity of the bis(4-acyloxybenzyl) and mono(4-acyloxybenzyl) esters of the 5′-monophosphate of AZT. J. Chem. Soc. Perkin Trans. 1239-1245.
73. Raetz, C.R., Chu, M.Y., Srivastava, S.P. and Turcotte, J.G. (1977) A Phospholipid derivative of cytosine arabinoside and its conversion to phosphatidylinositol by animal tissue. Science 196, 303-305.
74. Turcotte, J.G., Srivastava, S.P., Meresak, W.A., Rizkalla, B.A., Louzon, F. and Wunz, T.P. (1980) Cytotoxic liponucleotide analogs. I. Chemical synthesis of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety. Biochim. Biophys. Acta 619, 604-618.
75. Turcotte, J.G., Srivastava, S.P., Steim, J.M., Calabresi, P., Tibbetts, L.M. and Chu, M.Y. (1980) Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety. Biochim. Biophys. Acta 619, 619-631.
76. Ryu, E.K., Ross, R.J., Matsushita, T., MacCoss, M., Hong, C.I. and West, C.R. (1982) Phospholipid-nucleosidic conjugates. 3. Synthesis and preliminary biological evaluation of 1-beta-D-arabinofuranosylcytosine 5′-monophosphate-L-1,2,-dipalmitin and selected 1-beta-D-arabinofuranosylcytosine 5′-diphosphate-L-1,2-diacylglycerols. J. Med. Chem. 25, 1322-1329.
77. Maccoss, M., Edwards, J.J., Seed, T.M. and Spragg, S.P. (1982) Phospholipid-nucleoside conjugates. The aggregational characteristics and morphological aspects of selected 1-beta-D-arabinofuranosylcytosine 5′-diphosphate-L-1,2-diacylglycerols. Biochim. Biophys. Acta 719, 544-555.
78. Hostetler, K.Y., Parker, S., Sridhar, C.N., Martin, M.J., Li, J., Stuhmiller, L.M., Van Wijk, G.M.T., Van den Bosch, H., Gardner, M.F., Aldern, K.A. and Richman, D.D. (1993) Acyclovir diphosphate dimyristoylglycerol: A phospholipid prodrug with activity against acyclovir-resistant herpes simplex virus. Proc. Natl. Acad. Sci. USA 90, 11835-11839.
79. Steim, J.M., Neto, C.C., Sarin, P.S., Sun, O.K., Sehgai, R.K. and Turcotte, J.G. (1990) Lipid conjugates of antiretroviral agents. I. Azidothymidine monophosphate-diglyceride: Anti-HIV activity, physical properties and interaction with plasma proteins. Biochem. Biophys. Res. Commun. 171, 451-457.
80. Van Wijk, G.M.T., Hostetler, K.Y., Suurmeijer, C.N.S.P. and Van den Bosch, H. (1992) Synthesis, characterization and some properties of dideoxynucleoside analogs of cytidine diphosphate diacylglycerol. Biochim. Biophys. Acta 1165, 45-52.
81. Sakai, A., Mori, N., Shuto, S. and Suzuki, T. (1993) Deacylation-reacylation cycle: A possible absorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats. J. Pharm. Sci. 82, 575-578.
82. Matsushita, T., Ryu, E.K., Hong, C.I. and MacCoss, M. (1981) Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Cancer Res. 41, 2707-2713.
83. Rosenberg, I. and Holy, A. (1987) Synthesis of potential prodrugs and metabolites of 9-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)adenine. Coll. Czech. Chem. Commun. 52, 2792-2800.
84. Germershausen, J., Bostedor, R., Liou, R., Field, A.K., Wagner, A.F., MacCoss, M., Tolman, R.L. and Karkas, J.D. (1986) Comparison of the modes of antiviral action of 2′-nor-deoxyguanosine and its cyclic phosphate, 2′-nor-cyclic GMP. Antimicrobial Agents Chemother. 29, 1025-1031.
85. LePage, G.A. and Hersh, E.M. (1972) Cyclic nucleotide analogs as carcinostatic agents. Biochem. Biophys. Res. Commun. 46, 1918.
86. Gohil, R.N., Gillen, R.G. and Nagyvary, J. (1974) Synthesis and properties of some cyclic AMP alkyl phosphotriesters. Nucleic Acids Res. 1, 1691-1701.
87. Revankar, G.R., Huffman, J.H., Allen, L.B., Sidwell, R.W., Robins, R.K. and Tolman, R.L. (1975) Synthesis and antiviral activity of certain 5′-monophosphates of 9-D-Arabinofuranosyladenine and 9-D-arabinofuranosylhypoxanthine. J. Med. Chem. 18, 721-726.
88. Meyer, R.B. and Stone, T.E. (1979) 2′-O-Acyl-6-thioinosine cyclic 3′,5′-phosphates as prodrugs of thioinosinic acid. J. Med. Chem. 22, 811-815.
89. Long, R.A., Szekeres, G.L., Khwaja, T.A., Sidwell, R.W., Simon, L.N. and Robins, R.K. (1972) Synthesis and antitumor and antiviral activities of 1-beta-D-arabinofuranosylpyrimidine 3′,5′-cyclic phosphates. J. Med. Chem. 15, 1215-1218.
90. Beres, J., Sagi, G., Bentrude, W.G., Balzarini, J., De Clercq, E. and Otvos, L. (1986) Synthesis and antitumor and antiviral properties of 5-halo- and 5-(trifluoromethyl)-2′-deoxyuridine 3′,5′-cyclic monophosphates and neutral triesters. J. Med. Chem. 29, 1243-1249.
91. Farquhar, D., Kuttesch, N.J., Wilkerson, M.G. and Winkler, T. (1983) Synthesis and biological evaluation of neutral derivatives of 5-fluoro-2′-deoxyuridine 5′-phosphate. J. Med. Chem. 26, 1153-1158.
92. Farquhar, D. and Smith, R. (1985) Synthesis and biological evaluation of 9-[5′-(2-oxo-1,3,2-oxazaphosphorinan-2-yl)-beta-D-arabinosyl]adenine and 9-[5′-(2-oxo-1,3,2-dioxaphosphorinan-2-yl)-beta-D-arabinosyl]-adenine: Potential precursors of 9-[beta-D-arabinofuranosyl]adenine 5′-monophosphate. J. Med. Chem. 28, 1358-1361.
93. Farquhar, D., Khan, S., Wilkerson, M.C. and Andersson, B.S. (1995) Biologically-cleavable phosphate protective groups: 4-acyloxy-1,3,2-dioxaphosphorinanes as neutral latent precursors of dianionic phosphates. Tetrahedron Lett. 36, 655-658.
94. Farquhar, D., Chen, R. and Khan, S. (1995) 5′-[4-(Pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2′-deoxy-5- fluorouridine: A membrane-permeating prodrug of 5-fluoro-2′-deoxyuridic acid (FdUMP). J. Med. Chem. 38, 488-495.
95. Hunston, R.N., Jones, A.S., McGuigan, C., Walker, R.T., Balzarini, J. and De Clercq, E. (1984) Synthesis and biological properties of some cyclic phosphotriesters derived from 2′-deoxy-5-fluorouridine. J. Med. Chem. 27, 440-444.
96. Wechter, W.J. (1967) Nucleic acids. I. The synthesis of nucleotides and dinucleoside phosphates containing ara-cytidine. J. Med. Chem. 10, 762-773.
97. Smith, C.G., Buskirk, H.H. and Lummis, W.L. (1967) Nucleic acids. II. Cytotoxicity studies with nucleotides and dinucleoside phosphates containing ara-cytidine. J. Med. Chem. 10, 774-776.
98. Renis, H.E., Hollowell, C.A. and Underwood, G.E. (1967) Nucleic acids. III. Antiviral activity of nucleotides and dinucleoside phosphates containing ara-cytidine. J. Med. Chem. 10, 777-782.
99. Zeleznick, L.D. (1969) Nucleic acids - X. Enzymatic hydrolysis of dinucleoside phosphates containing ara-cytidine (cytarabine). Biochem. Pharmacol. 18, 855-862.
100. Schinazi, R.F., Sommadossi, J.-P., Saalmann, V., Cannon, D.L., Xie, M.-Y., Hart, G.C., Smith, G.A. and Hahn, E.F. (1990) Activities of 3′-azido-3′-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrobial Agents Chemother. 34, 1061-1067.
101. Hahn, E.F., Busso, M., Mian, A.M. and Resnick, L. (1989) Nucleotide dimers as anti human immunodeficiency virus agents. In: J.C. Martin (Ed.), Nucleotide Analogs as Antiviral Agents. Am. Chem. Soc., Washington, DC, pp. 156-159.
102. Schott, H., Haussler, M.P., Gowland, P., Horber, D.H. and Schwendener, R.A. (1994) Synthesis and some properties of, amphiphilic dinucleoside phosphate derivatives of 3′-azido-2′,3′-dideoxythymidine (AZT). Antiviral Chem. Chemother. 5, 387-394.
103. Schott, H., Haussler, M.P., Gowland, P., Bender, A., Von Breissen, H. and Schwendener, R.A. (1995) Synthesis and in vitro antiviral properties of amphiphilic dinucleoside phosphate derivatives of 2′,3′-dideoxycytidine (ddC). Antiviral Chem. Chemother. 6, 320-326.
104. Schott, H., Haussler, M.P. and Schwendener, R.A. (1993) Synthesis and properties of N4-hexadecyl-2′-deoxycytidyl-(3′-5′)-5-ethyl-2′- deoxuridine and 2′-deoxythymidylyl-(3′-5′)-N4-hexadecyl-1-β-D- arabinofuranosylcytosine, two representatives of a new kind of prodrugs. Leibigs Ann. Chem. 277-282.
105. Shimizu, S.I., Balzarini, J., De Clercq, E. and Walker, R.T. (1992) The synthesis and biological properties of some aryl bis(nucleosid-5′-yl) phosphates using nucleosides with proven anti-HIV activity. Nucleosides Nucleotides 11, 583-594.
106. Routledge, A., Walker, I., Freeman, S., Hay, A. and Mahmood, N. (1995) Synthesis, bioactivation and anti-HIV activity of 4-acyloxybenzyl bis(nucleosid-5′-yl) phosphates. Nucleosides Nucleotides. 14, 1545-1558.
107. Rosowsky, A., Saha, J., Fazely, F., Koch, J. and Ruprecht, R.M. (1990) Inhibition of human immunodeficiency virus type I replication by phosphonoformate esters of 3′-azido-3′-deoxythymidine. Biochem. Biophys. Res. Commun. 172, 288-94.
108. Iyengar, B.S., Dorr, R.T. and Remers, W.A. (1991) Additional nucleotide derivatives of mitosenes. Synthesis and activity against parenteral and multidrug resistant L1210 leukemia. J. Med. Chem. 34, 1947-1951.
109. Meier, C., Neumann, J.M., Andre, F., Henin, Y. and Huynh-Dinh, T. (1992) O-Alkyl-5′,5′-dinucleoside phosphates as prodrugs of 3′-azidothymidine and cordycepin. J. Org. Chem. 57, 7300-7308.
110. Furman, P.A., St. Clair, M., Fyfe, J.A., Rideout, J.L., Keller, P.M. and Elion, G.B. (1979) Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate. J. Virol. 32, 72-76.
111. Sergheraert, C., Pierlot, C., Tartar. A., Henin, Y. and Lemaitre, M. (1993) Synthesis and anti-HIV evaluation of D4T and D4T 5′-monophosphate prodrugs. J. Med. Chem. 36, 826-830.
112. Gouyette, C., Neumann, J.M., Fauve, R. and Huynh-Dinh, T. (1989) 6- and 1-substituted mannosyl phosphotriesters as lipophilic macrophage-targeted carriers of antiviral nucleosides. Tetrahedron Lett. 30. 6019-6022.
113. Le Bec, C. and Huynh-Dinh, T. (1991) Synthesis of lipophilic phosphate triester derivatives of 5-fluorouridine and arabinocytidine as anticancer prodrugs. Tetrahedron Lett. 32, 6553-6556.
114. Henin, Y., Gouyette, C., Schwartz, O., Debouzy, J.C., Neumann, J.M. and Huynh-Dinh, T. (1991) Lipophilic glycosyl phosphotriester derivatives of AZT: Synthesis, NMR transmembrane transport study, and antiviral activity. J. Med. Chem. 34, 1830-1837.
115. Namane, A., Gouyette, C., Fillion, M.P., Fillion, G. and Huynh-Dinh, T. (1992) Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J. Med. Chem. 35, 3039-3044.
116. Puech, F., Gosselin, G., Lefebvre, I., Pompon, A., Aubertin, A., Kirn, A. and Imbach, J. (1993) Intracellular delivery of nucleoside monophosphates through a reductase-mediated activation process. Antiviral Res. 22, 155-174.
117. Perigaud, C., Gosselin, G., Lefebvre, I., Girardet, J., Benzaria, I., Barber, I. and Imbach, J. (1993) Ratioanal design for cytosolic delivery of nucleoside monophosphates: 'SATE' and 'DTE' as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 3, 2521-2526.
118. Lefebvre, I., Perigaud, C., Pompon, A., Aubertin, A.-M., Girardet, J.-L., Kirn, A., Gosselin, G. and Imbach, J.-L. (1995) Mononuc eoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: Intracellular delivery of 3′-azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 38, 3941-3950.
119. Krapcho, J., Turk, C., Cushman, D.W., Powell, J.R., DeForrest, J.M., Spitzmiller, E.R., Karenewsky, D.S., Duggan, M., Rovnvak, G., Schwartz, J., Natarajan, S., Godfrey, J.D., Ryono, D.E., Neubeck, R., Atwal, K.S. and Petrillo, E.W.J. (1988) Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide and phosphinic acid inhibitors incorporating 4-substituted prolines. J. Med. Chem. 31, 1148-1160.
120. Cushman, D.W., Ondetti, M.A., Gordon, E.M., Natarajan, G.S., Karanewsky D.S., Krapcho, J. and Petrillo, E.W., Jr. (1987) Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme. J. Cardiovasc. Pharmacol. 10, S17-S30.
121. Thorsett, E.D., Harris, E.E., Peterson, E.R., Greenlee, W.J., Patchett, A.A., Ulm, E.H. and Vasil, T.C. (1982) Phosphorus-containing inhibitors of angiotensin converting enzyme. Proc. Natl. Acad. Sci. USA 79, 2176-2180.
122. Dean, A.V., Kripalani K.J., Everett, D.W. and Migdalof, B.H. (1986) Disposition of fosinopril sodium (F) in bile duct cannulated (BDC) rats. Pharmacol. Res. 3, 152S.
123. Singhvi, S.M., Vasil, T.C., Kripalani, K.J., Dean, A.V. and Migdalof, B.H. (1986) Disposition of fosenopril sodium (F) in dogs and monkeys. Pharmacol. Res. 3, 152S.
124. Singhvi, S.M., Duchin, K.L., Morrison, R.A., Willard, D.A., Everett, D.W. and Frantz, M. (1988) Disposition of fosinopril sodium n healthy subjects. Br. J. Clin. Pharmacol. 25, 9-15.
125. Morrison, R.A., Singhvi, S.M., Pocetti, D.A., Peterson, A.E. and Migalof, B.H. (1987) Sites of first-pass bioactivation of fosincpril sodium in dogs. Pharmacologist 29, 30.
126. Weber, M.A. (1992) Fosinopril: A new generation of angiotensin-converting enzyme inhibitors. J. Cardiovasc. Pharmacol. 20 (Suppl. 10), S7-S12.
127. 14C-fosinopril sodium in dogs. Drug Metab. Dispos. 18, 253-257.
128. Ranadive, S.A., Chen, A.X. and Serajuddin, A.T.M. (1992) Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. 9, 1480-1486.
129. Friedman, D.I. and Amidon, G.L. (1989) Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: Enalapril and fosinopril. Pharm. Res. 6, 1043-1047.
130. Duchin, K.L., Waclawski, A., Tu, J.M., Manning, J., McKown, J. and Willard, D.A. (1985) Multiple-dose safety and pharmacologic study of SQ 28,55 in healthy subjects. J. Clin. Pharmacol. 25, 464.
131. Ford, N.F., Lasseter, K.C., Van harken, D.R., Hammet, J.L., Raymond, R. and Manning, J. (1995) Single-dose and steady-state pharmacokinetics of fosinopril and fosinoprilat in patients with hepatic impairment. J. Clin. Pharmacol. 35, 145-150.
132. Cushman, D.W., Wang, F.L., Fung, W.C., Grover, G.C., Harvey, C.M., Scalese, R.J., Mitch, S.L. and Deforrest, J.M. (1989) Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE). Br. J. Clin. Pharmacol. 28, 115s-131s.
133. Powell, J.R., DeForrest, J.M., Cushman, D.W., Rubin, B. and Petrillo, E.W. (1984) Antihypertensive effects of a new angiotensin converting enzyme (ace) inhibitor, SQ 28,555. Fed. Proc. Fed. Am. Soc. Exp. Biol. 43, 733
134. DeForrest, J.M., Waldron, T.L., Harvey, C., Scalese, B., Rubin, B., Powell, J.R., Petrillo, E.W. and Cushman, D.W. (1989) Fosinopril, a phosphinic acid inhibitor of angiotensin I converting enzyme: In vitro and preclinical in vivo pharmacology. J. Cardiovasc. Pharmacol. 14, 730-736.
135. Atack, J.R., Cook, S.M., Watt, A.P., Fletcher, S.R. and Ragan, C.I. (1993) In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J. Neurochem. 60, 652-658.
136. Atack, J.R., Prior, A.M., Fletcher, S.R., Quirk, K., McKeckren, R. and Ragan, C.I. (1994) Effects of L-690,488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,330, on phosphatidylinositol cycle markers. J. Pharmacol. Exp. Ther. 270, 70-76.
137. Espinal, J. (1988) What is the role of the insulin receptor tyrosine kinase? Trends Biochem. Sci. 13, 367-368.
138. Saperstein, R., Pasquale, V.P., Strout, H.V., Brady, E., Slater, E.E., Greenlee, W.J., Ondeyka, D.L., Patchett, A.A. and Hangauer, D.G. (1989) Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells. Biochemistry 28, 5694-5701.
139. Schultz, C., Vajanaphanich, M., Harootunian, A.T., Sammak, P.J., Barrett, K.E. and Tsein, R.Y. (1993) Acetoxymethyl esters of phosphates, enhancement of the permeability and potency of cAMP. J. Biol.Chem. 268, 6316-6322.
140. Hong, C.I., An, S.-H. Schliselfeld, L., Buchheit, D.J., Nechaev, A., Kirisits, A.J. and West, C.R. (1988) Nucleoside conjugates. 10. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5′-diphosphate-1,2-dipalmitins. J. Med. Chem. 31, 1793-1798.